Legal Status Overview
Gray AreaPeptides are in a legal gray zone in Maine because no Maine statute, administrative rule, or Board of Pharmacy chapter names peptides, 'research chemicals,' or research-use-only compounds as a distinct regulated category. Instead, Maine treats peptide-based drug products under its general Pharmacy Act and compounding rules, which incorporate the federal FDCA framework distinguishing FDA-approved drugs, 503A patient-specific compounding, and 503B outsourcing facility compounding. Where a peptide (e.g., semaglutide, tirzepatide) is FDA-approved or lawfully compounded by a Maine-licensed 503A/503B pharmacy under a valid prescription, it is legal to dispense; unapproved research peptides marketed for human use fall outside any explicit Maine rule and are governed mainly by federal FDA unapproved-new-drug enforcement rather than state-specific law.
Key Points
- Maine has no statute, administrative rule, or Board of Pharmacy chapter that specifically names peptides like BPC-157, TB-500, or 'research chemicals' as a distinct regulated category. [1]
- In Maine, an FDA-approved or lawfully compounded peptide dispensed on a valid prescription through a licensed Maine pharmacy is legal, while unapproved 'research use only' peptides sold for human use sit in an unresolved gray zone under state law. [2]
- The Maine Board of Pharmacy, created and empowered under the Maine Pharmacy Act (Title 32, Chapter 117), licenses pharmacies and pharmacists and sets the compounding standards that govern how any drug, including peptide-based products, may be prepared and dispensed in the state. [3]
- Maine legislation, including LD 1315 (An Act To Ensure the Safety of Compounded Drugs), restricts hospitals, nursing facilities, and ambulatory surgical facilities from purchasing compounded drugs from a pharmacy or entity not licensed in the state, reinforcing that compounded peptide products must come through state-licensed compounding channels. [4]
- The Maine Legislature has considered bills such as LD 480/HP0395 to require MaineCare reimbursement for FDA-approved GLP-1 receptor agonist drugs for obesity, with prescriber and prior-authorization limits, rather than addressing unapproved research peptides. [5]
- A person cannot lawfully bring or buy unapproved research-use-only peptides like BPC-157 for personal human use in Maine, since no state exemption exists and such products remain unapproved new drugs under federal FDA law that Maine has not carved out an exception for. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- The Maine Prescription Drug Affordability Board's 2025 review of GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) focused on cost and affordability of FDA-approved obesity medications rather than on compounded or research-grade versions of these peptides. [6]
Peptide-by-peptide status in Maine
| BPC-157 | BPC-157 has no Maine-specific legal status and is not FDA-approved, so in Maine it can only be lawfully obtained through a licensed compounding pharmacy under a valid prescription, while research-use-only BPC-157 sold for human use sits in a legal gray zone that also faces federal restriction after FDA safety concerns. [2] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | FDA-approved GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) are legal in Maine when prescribed and dispensed through licensed Maine pharmacies, and the state has focused legislative attention (e.g., LD 480) on insurance coverage for these approved versions rather than on compounded copies. [5] |
| TB-500 | TB-500 is not named in any Maine statute or Board of Pharmacy rule, meaning it falls under the same general gray-zone treatment as other unapproved research peptides in Maine, with no state-specific carve-out found. [1] |
| Human Growth Hormone (HGH/somatropin) | Human growth hormone is an FDA-approved prescription drug that in Maine may only be lawfully dispensed by a licensed pharmacy pursuant to a valid prescription under the state's general Pharmacy Act framework, with no Maine-specific HGH statute identified beyond that general prescription-drug structure. [3] |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides in Maine without a prescription?
No -- in Maine, FDA-approved peptide drugs may only be legally sold through a licensed pharmacy with a valid prescription, and unapproved 'research use only' peptides marketed for human use are not authorized for over-the-counter sale under any Maine-specific exemption. [2]
Is it legal to import or travel with peptides into Maine?
There is no Maine-specific rule on personally importing or traveling with peptides; unapproved research peptides like BPC-157 remain unapproved new drugs under federal law, so bringing them into Maine for human use is not affirmatively authorized by any state exemption.
Can a telehealth provider prescribe peptides like semaglutide to patients in Maine?
A telehealth provider can prescribe FDA-approved peptide drugs such as semaglutide to Maine patients only if the prescriber is properly licensed and the prescription is filled by a pharmacy operating under Maine's Pharmacy Act and Board of Pharmacy rules; no Maine-specific telehealth carve-out for research-grade peptides was found. [3]
What happens if a compounding pharmacy in Maine sells compounded peptide products improperly?
Under Maine law such as LD 1315 (An Act To Ensure the Safety of Compounded Drugs), health care facilities are barred from purchasing compounded drugs, including peptide products, from pharmacies or entities not licensed in Maine, reflecting the state's enforcement approach of channeling compounding through licensed, inspected pharmacies rather than penalizing peptides as a named category. [4]
Is BPC-157 legal in Maine?
BPC-157 is not named in any Maine statute, so its legal status in Maine is a gray zone: it is not affirmatively banned by state law, but it is also not an FDA-approved drug, meaning it cannot be lawfully sold for human use outside a licensed compounding pharmacy's prescription-based dispensing. [2]